Lantern Pharma (LTRN) AI Stock Analysis

• Market Cap: $32.25M
• Dividend Yield: N/A
• Average Volume (3M): 32.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.41
• Revenue Growth: N/A
• EPS Growth: -31.16%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.93
• Shares Outstanding: 10,784,725
• 10 Day Avg. Volume: 33,354
• 30 Day Avg. Volume: 32,630
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $25.00
• Price Target Upside: 736.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Lantern Pharma's stock score is constrained by its significant financial challenges, including a lack of revenue and negative cash flows. While technical indicators suggest potential for a short-term rebound, the company's unattractive valuation and need for substantial additional funding present risks. Strategic advancements in AI-driven oncology drug development provide some long-term promise, but financial sustainability remains a critical concern.

Lantern Pharma Business Overview & Revenue Model

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

How the Company Makes Money

Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Financial Statement Overview

Summary

Lantern Pharma's financial health shows significant challenges, primarily due to its inability to generate revenue and increasing operational losses. While its balance sheet is relatively robust with low debt levels, the cash flow situation raises concerns about long-term viability and the need for additional financing if operational metrics do not improve.

Income Statement

Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.

Balance Sheet

The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.

Cash Flow

Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
261.05K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
170.47K	0.00	-174.84K	-154.68K	-97.42K	-3.39K
	EBIT
-21.20M	-22.22B	-17.88M	-14.43M	-12.59M	-5.91M
	EBITDA
-21.18M	-22.22B	-15.79M	-14.42M	-12.27M	-5.90M
	Net Income Common Stockholders
-19.09M	-20.78B	-15.96M	-14.09M	-12.30M	-5.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
55.20M	24.01B	41.30M	55.20M	70.73M	19.23M
	Total Assets
58.84M	25.57B	43.65M	58.84M	73.95M	20.36M
	Total Debt
52.89K	243.66M	234.47K	52.89K	204.95K	108.50K
	Net Debt
-37.15M	-7.27B	-21.70M	-37.15M	-51.32M	-19.12M
	Total Liabilities
2.80M	4.38B	2.74M	2.80M	2.38M	660.84K
	Stockholders Equity
56.04M	21.19B	40.91M	56.04M	71.57M	19.70M
Cash Flow		Free Cash Flow
-17.24M	-17.81B	-14.37M	-12.80M	-10.61M	-5.67M
	Operating Cash Flow
-17.23M	-17.81B	-14.35M	-12.77M	-10.59M	-5.65M
	Investing Cash Flow
178.29K	3.37B	-930.21K	179.27K	-19.53M	-16.14K
	Financing Cash Flow
-433.29K	66.71M	-500.00K	―	63.42M	23.66M

Lantern Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Negative. The current price of 2.99 is below the 20-day moving average (MA) of 3.60, below the 50-day MA of 4.11, and below the 200-day MA of 3.89, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 34.43 is Neutral, neither overbought nor oversold. The STOCH value of 10.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LTRN.

Lantern Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.35B	1.19	-46.87%	2.63%	17.16%	1.34%
SRRK	45 Neutral	$2.55B	―	-82.95%	―	―	-22.34%
LTRN	43 Neutral	$32.25M	―	-66.93%	―	―	-31.16%
FATE	42 Neutral	$86.28M	―	-54.21%	―	-78.55%	-0.92%
BDSX	39 Underperform	$83.27M	―	-337.30%	―	45.30%	45.67%
IGMS	29 Underperform	$67.55M	―	-155.76%	―	25.77%	32.56%
ATHA	26 Underperform	$9.76M	―	-110.77%	―	―	18.61%

Lantern Pharma Corporate Events

Lantern Pharma Reports Q4 2024 Financial Results and AI Progress

On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.

Lantern Pharma Extends CSO’s Employment Agreement

Lantern Pharma Inc.’s Board of Directors has approved an amendment to the employment agreement for Kishor G. Bhatia, the Chief Scientific Officer. The amendment extends the agreement’s term to January 15, 2026, adjusts his working hours to 24 per week, and sets his annual base salary at $189,600, effective from the first pay period in January 2025.